SGCE (Epsilon-Sarcoglycan) in Humans: Function, Localization, and Biological Roles

Overview of SGCE and Epsilon-Sarcoglycan

The SGCE gene encodes epsilon-sarcoglycan, a transmembrane glycoprotein that is part of the sarcoglycan family. Sarcoglycans are components of the dystrophin-associated glycoprotein complex (DGC), which links the cytoskeleton to the extracellular matrix in muscle and other tissues (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Like other sarcoglycans, epsilon-sarcoglycan is a single-pass membrane protein with a large N-terminal extracellular domain, a hydrophobic transmembrane segment, and a small cytoplasmic tail (www.dmd.nl) (pmc.ncbi.nlm.nih.gov). The SGCE protein (~437 amino acids, ~43–50 kDa) contains several conserved N-linked glycosylation sites and cysteine residues in its extracellular region, suggesting it is a heavily glycosylated, disulfide-bonded protein (www.dmd.nl). These features are characteristic of the sarcoglycan family and are important for proper folding, stability, and membrane localization. Importantly, SGCE is subject to genomic imprinting: the maternal allele is typically silenced, so only the paternal copy is expressed in most tissues (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). This parent-of-origin effect results in autosomal-dominant inheritance with reduced penetrance – pathogenic variants usually cause disease only when inherited from the father (www.ncbi.nlm.nih.gov). More than 40 alternative transcript isoforms of SGCE have been reported, including several that are brain-specific, indicating complex regulation and potentially specialized functions in different cell types (pubmed.ncbi.nlm.nih.gov). Overall, SGCE encodes a structural membrane protein that plays key roles in muscle integrity and neuronal function, with unique genetic regulation (imprinting) influencing its expression and disease inheritance.

Structural Role in Muscle and the Dystrophin Complex

In skeletal and cardiac muscle, epsilon-sarcoglycan is a component of the sarcoglycan subcomplex within the DGC, which resides at the muscle cell plasma membrane (the sarcolemma) (www.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The DGC forms a physical link between the intracellular cytoskeleton (via dystrophin and associated proteins) and the extracellular matrix (via dystroglycan binding to laminin). This complex stabilizes the sarcolemma, protecting muscle fibers from damage during contraction and stretching (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The sarcoglycan subunits (α, β, γ, δ, and others) assemble into a tight multimERIC complex together with a small transmembrane protein called sarcospan, strengthening the connection between dystroglycan and the cytoskeleton (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Epsilon-sarcoglycan is highly similar in structure to α-sarcoglycan (about 60% sequence identity) and is considered a type I membrane protein (extracellular N-terminus) (pmc.ncbi.nlm.nih.gov). Notably, epsilon-sarcoglycan can functionally substitute for α-sarcoglycan in muscle: experimental overexpression of epsilon-sarcoglycan in α-sarcoglycan–deficient mice was able to rescue the muscular dystrophy phenotype (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This suggests that epsilon- and α-sarcoglycan have overlapping roles in providing mechanical stability to the muscle membrane. Indeed, in striated muscle the predominant sarcoglycan complex uses α-sarcoglycan, but in some contexts epsilon-sarcoglycan is present at lower levels (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). All sarcoglycans in muscle work cooperatively: loss of any one sarcoglycan destabilizes the entire complex, leading to mislocalization and degradation of the remaining subunits (pmc.ncbi.nlm.nih.gov). Thus, the primary molecular function of epsilon-sarcoglycan in muscle is structural – it integrates into the DGC to maintain sarcolemmal integrity and resist mechanical stress (often termed a “mechanoprotective” role) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Beyond this mechanical role, the sarcoglycan–sarcospan subcomplex has been implicated in signal transduction; for example, it may influence cell signaling pathways in muscle fibers, although these non-mechanical roles are not fully understood (pmc.ncbi.nlm.nih.gov).

Epsilon-sarcoglycan’s contribution is especially prominent in smooth muscle. Unlike striated muscle (which uses α-sarcoglycan), smooth muscle predominantly incorporates epsilon-sarcoglycan into its DGC. Studies have shown that in vascular smooth muscle, ε-sarcoglycan replaces α-sarcoglycan in the complex, partnering with β-, δ-, and ζ-sarcoglycan to form a unique tetrameric assembly (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). (γ-Sarcoglycan is largely absent in smooth muscle and is replaced by the ζ isoform in this tissue (pmc.ncbi.nlm.nih.gov).) This smooth muscle complex still connects with dystrophin/utrophin and dystroglycan, indicating that epsilon-sarcoglycan fulfills the same adhesive function as α-sarcoglycan in linking the muscle cell cortex to the extracellular matrix (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Consistently, epsilon-sarcoglycan is detected at the sarcolemma of various muscle types (cardiac, smooth, and to a lesser extent skeletal muscle) and localizes to the plasma membrane in those cells (www.dmd.nl) (pubmed.ncbi.nlm.nih.gov). The presence of epsilon-sarcoglycan in smooth muscle DGCs may explain why SGCE mutations do not cause the limb-girdle muscular dystrophies seen with mutations in α-, β-, γ-, or δ-sarcoglycan (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In skeletal muscle, the abundant α-sarcoglycan can compensate for loss of epsilon-sarcoglycan, whereas smooth muscle and certain non-muscle tissues rely on epsilon-sarcoglycan as the primary isoform (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, within muscle tissues SGCE’s product functions as a structural adapter in the dystrophin complex – anchoring the cytoskeleton to the extracellular matrix, preserving membrane stability, and possibly participating in mechanosensory signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Role in the Nervous System: Synaptic Function and Signaling

A defining feature of SGCE is its prominent expression in the central nervous system (CNS) and its necessity for normal neuronal function. Epsilon-sarcoglycan is highly expressed in the brain, especially in neurons of the cerebral cortex, basal ganglia, hippocampus, cerebellum, and olfactory bulb (pubmed.ncbi.nlm.nih.gov). Immunolocalization and biochemical studies demonstrate that epsilon-sarcoglycan is targeted to the neuronal plasma membrane, similar to its sarcolemmal localization in muscle (pubmed.ncbi.nlm.nih.gov). Recent research has shown that epsilon-sarcoglycan is actually incorporated into DGC-like complexes in the brain. In 2016, Waite et al. purified sarcoglycan-containing complexes from mouse brains and identified epsilon-sarcoglycan co-assembling with β-, δ-, γ-, and ζ-sarcoglycan, confirming that a prototypical sarcoglycan complex exists in the brain (pmc.ncbi.nlm.nih.gov). Furthermore, under gentle extraction conditions, the brain sarcoglycan complex co-purified with known components of the dystrophin-associated protein complex (such as dystroglycans and dystrophin/utrophin), indicating that epsilon-sarcoglycan in neurons is part of a larger DGC that likely mirrors the muscle DGC (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, SGCE is predominantly expressed in neurons, with additional lower expression in certain glial cells (e.g. perivascular astrocytes) and in brain blood vessels (pmc.ncbi.nlm.nih.gov). This widespread distribution set the stage for understanding SGCE’s role in neural circuitry.

Emerging evidence indicates that epsilon-sarcoglycan plays a crucial role in synaptic organization, particularly at inhibitory (GABAergic) synapses. A 2021/2022 study by Cazurro-Gutiérrez et al. and subsequent analyses have provided compelling data that epsilon-sarcoglycan functions as a scaffold in GABAergic synapses, stabilizing synaptic proteins and neurotransmitter receptors (pmc.ncbi.nlm.nih.gov). Epsilon-sarcoglycan has been found localized in a punctate “spot-like” pattern at synapses in neurons, often co-distributed with GABA_A receptors in regions such as hippocampal pyramidal neurons and cerebellar Purkinje cells (pmc.ncbi.nlm.nih.gov). This spatial association suggests that epsilon-sarcoglycan helps organize or anchor GABA_A receptor clusters and other synaptic components in the postsynaptic membrane (pmc.ncbi.nlm.nih.gov). Indeed, loss of SGCE disrupts GABAergic neurotransmission: in SGCE-deficient mouse models, researchers observed impaired clustering of GABA_A receptors, reduced tonic inhibitory currents, and deficits in synaptic inhibition (pmc.ncbi.nlm.nih.gov). These functional changes culminate in motor phenotypes (myoclonic jerks and dystonia-like movements) that resemble the human myoclonus-dystonia syndrome, strongly linking epsilon-sarcoglycan’s molecular role to inhibitory neural circuit function (pmc.ncbi.nlm.nih.gov). In summary, current understanding is that epsilon-sarcoglycan helps maintain proper GABAergic synaptic transmission by stabilizing inhibitory synapse structure and receptor localization (pmc.ncbi.nlm.nih.gov). This could be through direct or indirect interaction with known synaptic scaffolding systems – for example, the dystrophin–dystroglycan complex at central synapses is known to associate with GABA_A receptor clusters and stabilize them (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Loss of dystrophin in the brain (as in Duchenne muscular dystrophy) also leads to abnormal GABA_A receptor distribution and synaptic electrophysiology defects (pmc.ncbi.nlm.nih.gov). By analogy, epsilon-sarcoglycan (as part of the same complex) appears to be critical for the integrity of inhibitory synapses and neural network balance. Its disruption likely causes an imbalance in neurotransmission – specifically a deficit in inhibitory signaling – which can manifest as the hyperkinetic movements and dystonia seen in SGCE-associated disease (pmc.ncbi.nlm.nih.gov).

Beyond synapses, epsilon-sarcoglycan may have additional roles in the nervous system. The DGC in brain has been implicated in calcium homeostasis and signaling in neurons (pmc.ncbi.nlm.nih.gov). Patients with muscular dystrophies (lacking various DGC components) sometimes show abnormal neuronal Ca²⁺ handling and cognitive or behavioral changes (pmc.ncbi.nlm.nih.gov), suggesting the DGC (and by extension sarcoglycans) influence neuronal signaling pathways. In line with this, one hypothesis is that loss of epsilon-sarcoglycan could perturb Ca²⁺-dependent signaling cascades in certain neurons, potentially contributing to neurologic symptoms (pmc.ncbi.nlm.nih.gov). There is also evidence for epsilon-sarcoglycan expression in the retina and in glial structures of the CNS. For instance, multiple sarcoglycan subunits (β, δ, γ, ε) are present at the inner and outer limiting membranes of the retina, co-localizing with Müller glial cell endfeet (pmc.ncbi.nlm.nih.gov). Interestingly, this retinal sarcoglycan distribution occurs even in the absence of dystrophin, indicating sarcoglycans may form alternative membrane complexes beyond the canonical DGC (pmc.ncbi.nlm.nih.gov). In the retina, sarcoglycans (possibly including epsilon-sarcoglycan) might contribute to maintaining glial cell polarity, adhesion, or blood-retina barrier function, rather than synaptic transmission (pmc.ncbi.nlm.nih.gov). Similarly, a recent study detected all sarcoglycan transcripts (including SGCE) in purified brain microvasculature; δ- and ε-sarcoglycan were enriched in larger blood vessels (pmc.ncbi.nlm.nih.gov). This raises the possibility that epsilon-sarcoglycan helps support the neurovascular unit – perhaps influencing blood-brain barrier integrity or mechanotransduction in cerebral blood vessels (pmc.ncbi.nlm.nih.gov). While these non-synaptic roles are still speculative, they underscore that SGCE’s function in the nervous system is multifaceted. In summary, epsilon-sarcoglycan in the CNS primarily acts at the cell surface of neurons (and some glia), where it is integral to the architecture and stability of inhibitory synapses, and it may also participate in broader aspects of neural cell membrane organization and signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Cellular Localization and Expression Pattern

Subcellular localization: Epsilon-sarcoglycan is an integral membrane protein found at the plasma membrane of cells. It is a type I membrane protein, meaning its N-terminus is located extracellularly (after a cleaved signal peptide) and it has a short C-terminal cytoplasmic tail (www.dmd.nl). Consistent with this topology, SGCE protein undergoes co-translational insertion into the endoplasmic reticulum, is glycosylated in the ER/Golgi, and trafficks via the secretory pathway to the cell surface. In healthy cells, epsilon-sarcoglycan primarily resides at the cell surface membrane, often as part of larger protein complexes (e.g. the DGC at the sarcolemma or analogous complexes at synapses) (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For example, immunostaining shows epsilon-sarcoglycan at the sarcolemma of muscle fibers and at neuronal cell membranes in brain tissue (www.dmd.nl) (pubmed.ncbi.nlm.nih.gov). In neurons, high-resolution studies have observed epsilon-sarcoglycan in puncta at synaptic membranes (especially in postsynaptic regions of inhibitory synapses) (pmc.ncbi.nlm.nih.gov). Importantly, proper cell-surface localization of epsilon-sarcoglycan depends on correct folding and assembly with other sarcoglycan subunits. In vitro experiments have demonstrated that certain disease-causing missense mutations (e.g., H36P, H36R, L172R) in SGCE produce misfolded proteins that fail to traffic to the plasma membrane and are instead retained inside the cell (pubmed.ncbi.nlm.nih.gov). These trapped mutant proteins become polyubiquitinated and are rapidly degraded by the proteasome (pubmed.ncbi.nlm.nih.gov), indicating the cellular quality-control system recognizes and disposes of unassembled or misfolded epsilon-sarcoglycan. This observation mirrors the general requirement that the sarcoglycan subunits assemble into a complex in the ER for stability and forward transport (pmc.ncbi.nlm.nih.gov). If any one subunit (e.g., SGCE) is missing or mutant, the complex may not form correctly, and the proteins are often retained in the ER and degraded, rather than reaching the membrane (pmc.ncbi.nlm.nih.gov). Thus, under normal conditions, epsilon-sarcoglycan’s steady-state location is on the extracellular face of the plasma membrane, where it can interact with extracellular matrix components and other membrane proteins, while a small cytosolic tail faces inward and could interact with cytoskeletal or signaling molecules.

Tissue expression: The SGCE gene is expressed in a broad range of human tissues, with notable expression in the brain and muscles. Northern blot and mRNA profiling studies (late 1990s) found SGCE transcripts in all tissues examined, with moderate expression in brain, heart, skeletal muscle, lung, and placenta, and lower levels in kidney, liver, and pancreas (www.dmd.nl). This broad pattern suggests epsilon-sarcoglycan is not muscle-specific but has roles in multiple organ systems. Protein studies similarly detected a ~45 kDa epsilon-sarcoglycan protein at the membrane of heart, skeletal muscle, kidney, liver, and lung (www.dmd.nl). In the central nervous system, SGCE is highly expressed in neuronal tissue throughout the brain (pubmed.ncbi.nlm.nih.gov). Research in mice indicates Sgce expression is largely neuronal, with some presence in glial cells, and interestingly, transcripts for SGCE and other sarcoglycans are even found in brain endothelial cells (blood vessels) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In muscle tissues, there is a distinction between striated muscle and smooth muscle usage of SGCE: skeletal muscle fibers predominantly use α-sarcoglycan, but smooth muscle relies on SGCE (epsilon-sarcoglycan) as a key DGC component (pmc.ncbi.nlm.nih.gov). Epsilon-sarcoglycan is also present in cardiac muscle (which has features of both striated and smooth muscle) (www.dmd.nl). In the developing embryo, SGCE is expressed early (mouse embryonic day 8.5 and onward) (www.dmd.nl), implying a role in developmental processes such as early muscle and nervous system formation. Overall, SGCE’s expression profile is widespread, with particularly high relevance in the central nervous system, vascular and visceral (smooth) musculature, and cardiac tissue (www.ncbi.nlm.nih.gov) (www.dmd.nl). This distribution correlates with the observed phenotypes when SGCE is mutated (neurologic movement disorder without overt skeletal muscle disease) – brain and possibly certain muscle types are the primary sites of SGCE function in vivo (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Pathways and Biological Processes Involving SGCE

Mechanical stability and membrane integrity: In muscle cells, epsilon-sarcoglycan is a component of the DGC, which plays a crucial role in maintaining the integrity of the plasma membrane under mechanical stress (pmc.ncbi.nlm.nih.gov). By linking the internal actin cytoskeleton (via dystrophin) to the external basal lamina (via dystroglycan-laminin), the DGC distributes the forces generated during muscle contraction, preventing micro-tears in the sarcolemma. Although the exact function of the sarcoglycan complex was historically unclear, it is now evident that it has both mechanical and signaling roles in muscle (www.ncbi.nlm.nih.gov). Mechanically, epsilon-sarcoglycan (along with other sarcoglycans and sarcospan) strengthens the connection between α-/β-dystroglycan and the rest of the complex, essentially acting as a stabilizing strut in the membrane structure (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The presence of sarcoglycans has been shown to fortify the muscle fiber membrane against damage; when sarcoglycan genes are knocked out or mutated (as in limb-girdle muscular dystrophies), muscle fibers become fragile and susceptible to injury (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In smooth muscle and other cells, the SGCE-containing DGC likely serves a similar structural support role, and may also help muscle cells sense and respond to mechanical stretch (mechanotransduction). There is evidence that the DGC, including sarcoglycans, can modulate membrane signaling molecules – for instance, the complex can influence ion channels or signaling enzymes at the membrane. One example is that muscle DGC normally localizes neuronal nitric oxide synthase (nNOS) to the sarcolemma, affecting NO signaling in muscle; if the DGC is disrupted, nNOS mislocalizes, contributing to functional deficits (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). While nNOS interaction is mainly through syntrophins rather than sarcoglycan directly, it illustrates how DGC components (including sarcoglycans) participate in signaling pathways that regulate muscle cell homeostasis. In summary, SGCE in muscle is part of the pathway that connects structural integrity to biochemical signaling, ensuring that muscle membranes are both mechanically resilient and properly tuned to transmembrane signals.

Synaptic and signaling pathways in neurons: In the brain, SGCE is implicated in pathways related to synaptic transmission and neural excitability. By stabilizing GABA_A receptor clusters and associated proteins at inhibitory synapses, epsilon-sarcoglycan influences the GABAergic signaling pathway, which is essential for neural inhibition and network balance (pmc.ncbi.nlm.nih.gov). Disruption of SGCE leads to deficient GABAergic inhibitory transmission (less effective synaptic inhibition), which tips the excitation/inhibition balance and can produce hyperkinetic movement disorders (as seen in myoclonus-dystonia) (pmc.ncbi.nlm.nih.gov). Therefore, SGCE can be placed in the context of the neurotransmission pathway, particularly affecting inhibitory synapse function. It likely interacts—directly or indirectly—with known synaptic scaffold proteins (for example, gephyrin, which anchors GABA_A receptors, or dystrophin/utrophin at synapses) to maintain receptor localization. This places epsilon-sarcoglycan in a functional pathway with dystrophin and dystroglycan at central synapses, which collectively regulate clustering of certain neurotransmitter receptors and ion channels (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, the connection between SGCE and calcium signaling has been hypothesized. The DGC in muscle is known to modulate stretch-activated channels and calcium homeostasis; analogously, in neurons, an intact DGC (including epsilon-sarcoglycan) might influence Ca²⁺ influx or internal Ca²⁺ stores in response to activity (pmc.ncbi.nlm.nih.gov). Some forms of dystonia and muscular dystrophy show abnormal neuronal Ca²⁺ handling, and SGCE-related dystonia might converge on these calcium signaling pathways (pmc.ncbi.nlm.nih.gov). Indeed, researchers have noted that other dystonia and muscle-dystrophy genes (like ANO3 and ANO5, encoding Ca²⁺-activated channels) point toward calcium signaling as a common pathway in dystonic disorders (pmc.ncbi.nlm.nih.gov). Although SGCE’s precise biochemical signaling partners in neurons are still being investigated, current data suggest that epsilon-sarcoglycan is involved in the molecular pathways of synapse maintenance, inhibitory neurotransmission, and possibly ion homeostasis in the nervous system (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). It acts not as a classic signaling receptor or enzyme, but as a structural facilitator of signaling, ensuring that receptors and channels are correctly positioned and regulated at the cell membrane.

Clinical and Functional Implications (Myoclonus-Dystonia Syndrome)

The physiological importance of SGCE is highlighted by the effects of its loss-of-function mutations in humans. Heterozygous mutations in SGCE are the primary cause of myoclonus-dystonia (M-D) syndrome, also known as DYT11 dystonia (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Myoclonus-dystonia is a rare autosomal dominant movement disorder characterized by sudden, brief muscle jerks (myoclonus) and twisting postures or tremor (dystonia), often beginning in childhood or adolescence (pubmed.ncbi.nlm.nih.gov). The majority of pathogenic SGCE variants are loss-of-function (nonsense, frameshift, or missense causing misfolding), leading to deficient epsilon-sarcoglycan function. Due to maternal imprinting of SGCE, an affected individual usually has inherited a mutant allele from their father (paternal transmission); maternally inherited mutations are typically silenced, resulting in non-manifesting carriers (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). (This parent-of-origin effect causes reduced penetrance – only ~5% of maternally inherited SGCE mutations cause disease symptoms (www.ncbi.nlm.nih.gov).) The absence of muscle disease in SGCE mutation carriers is a striking contrast to mutations in the other sarcoglycan genes: α-, β-, γ-, and δ-sarcoglycan mutations cause limb-girdle muscular dystrophies, whereas ε-sarcoglycan mutations cause a neurological syndrome without direct muscle weakness (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This dichotomy is explained by the tissue-specific roles of the sarcoglycans. SGCE’s pathological effects reflect its critical function in the brain rather than in muscle (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In patients with SGCE mutations, muscle tissue generally remains intact (α-sarcoglycan and others maintain the muscle DGC), but in the brain, the loss of epsilon-sarcoglycan cannot be compensated by other isoforms, leading to neural dysfunction. Post-mortem and experimental studies have found no significant dystrophic changes in muscle from SGCE mutation carriers, corroborating that the primary site of dysfunction is the nervous system (pmc.ncbi.nlm.nih.gov). Meanwhile, studies in mouse models and neuronal cell culture have illuminated what goes wrong at the cellular level: neurons lacking functional epsilon-sarcoglycan show abnormal receptor clustering at inhibitory synapses and hyperexcitability, consistent with the clinical tremor and jerking phenotypes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, myoclonus-dystonia can be viewed as a synaptopathy caused by loss of SGCE’s stabilizing influence on synaptic membranes.

From a biochemical perspective, many SGCE mutations result in a “null” phenotype where no functional protein reaches the membrane. Experiments have shown that certain missense mutations prevent proper folding, causing the protein to accumulate in the endoplasmic reticulum and undergo degradation (via ubiquitin-proteasome pathways) before it ever functions (pubmed.ncbi.nlm.nih.gov). The cell’s failure to deliver epsilon-sarcoglycan to the surface means the entire sarcoglycan complex may be absent from neuronal membranes. Interestingly, cellular factors like torsinA, an ER chaperone ATPase implicated in another form of dystonia (DYT1), might influence SGCE mutant handling (pubmed.ncbi.nlm.nih.gov). One study found that wild-type torsinA can modulate the trafficking and degradation of mutant epsilon-sarcoglycan, whereas the dystonia-causing mutant torsinA (ΔE302/303) is less effective, hinting at a possible intersection of dystonia pathways at the level of protein homeostasis (pubmed.ncbi.nlm.nih.gov). Although torsinA’s assistance is not fully understood, this suggests that protein quality control in the secretory pathway is crucial for SGCE – if the quality control fails or is overwhelmed, misfolded SGCE may be degraded excessively, potentially exacerbating the loss of function.

Clinically, understanding SGCE’s function has direct implications. Genetic testing for SGCE mutations is now a standard component of the work-up for patients with unexplained myoclonic tremors or dystonia, especially if there is a family history consistent with paternal inheritance. GeneReviews and neurological guidelines emphasize testing SGCE in such cases and explain the imprinting effect to patients and families (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). For affected individuals, one “genetic counseling pearl” is that an SGCE mutation carrier has a 50% chance of passing the mutation to offspring, but if the mother is the carrier, the child’s risk of actual disease is much lower (~5% or less) due to maternal allele silencing (www.ncbi.nlm.nih.gov). This unusual inheritance pattern underscores SGCE’s unique regulation. There are currently no therapies that directly target the epsilon-sarcoglycan protein or replace its function in the brain. However, patients’ motor symptoms are often managed with medications (e.g. GABA-enhancing drugs like clonazepam or alcohol, which many patients find transiently improves myoclonus) (www.ncbi.nlm.nih.gov), and in severe cases deep brain stimulation has been used to alleviate dystonia. These treatments address the neural circuit dysfunction downstream of SGCE loss rather than the molecular defect itself.

On the research front, the link between SGCE and synaptic GABAergic function suggests that future therapies might aim to restore inhibitory synapse stability. For instance, one could envision gene therapy to reintroduce functional SGCE in the relevant neurons, or small molecules to enhance the clustering of GABA_A receptors even in the absence of epsilon-sarcoglycan. The feasibility of gene replacement is supported by the relatively small size of the SGCE coding sequence (~1.7 kb mRNA) (www.dmd.nl), which is amenable to viral vectors. Additionally, the success of epsilon-sarcoglycan in compensating for α-sarcoglycan in muscle (in mouse models) raises the possibility that epsilon-sarcoglycan or related proteins might substitute for each other if delivered to the right cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). No clinical trials of SGCE gene therapy have been reported to date, but SGCE remains a compelling candidate for further research given its clear, tissue-specific disease mechanism. In summary, the pathophysiological insights into SGCE function – from membrane stabilization to synaptic support – directly inform our understanding of myoclonus-dystonia and guide current diagnostic and counseling practices. They also open avenues for targeted interventions that might one day correct or mitigate the synaptic defects caused by SGCE mutations.

Recent Research and Emerging Insights (2021–2024)

Our understanding of SGCE has advanced significantly in recent years, with a number of authoritative studies and reviews from 2021–2024 refining the picture of epsilon-sarcoglycan’s role:

• Complex Isoforms and Brain-Specific Expression (2021): Cazurro-Gutiérrez et al. (2021) published a comprehensive review titled “ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene” that highlighted the complexity of the SGCE gene’s expression (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Over 40 SGCE isoforms were reported, including many alternative splicing variants uniquely present in the brain (pubmed.ncbi.nlm.nih.gov). This suggests that the protein may have diverse forms or interaction capabilities in different brain regions. The review noted that the exact role of epsilon-sarcoglycan remained elusive, but it hypothesized that SGCE is essential for normal synaptic function in the central nervous system (pubmed.ncbi.nlm.nih.gov). The authors proposed that disturbances in these brain-specific isoforms could be closely linked to the pathogenesis of myoclonus-dystonia. This perspective from 2021 underscored an important shift: SGCE was no longer viewed only as a muscle-related membrane protein but as a key neuronal protein with multiple isoforms modulating synaptic physiology.

• Epsilon-Sarcoglycan in Inhibitory Synapses (2022–2023): Building on the above, new experimental evidence emerged to support SGCE’s synaptic role. A pivotal study (referenced in a 2025 review by Nicita et al.) showed that epsilon-sarcoglycan directly contributes to GABAergic synapse stability (pmc.ncbi.nlm.nih.gov). In this study, researchers examined SGCE-knockout or mutant mice and observed deficits in GABA_A receptor clustering and inhibitory transmission, as described earlier. They concluded that SGCE loss leads to a specific impairment of GABAergic (inhibitory) signaling, which likely explains the network hyperexcitability in myoclonus-dystonia (pmc.ncbi.nlm.nih.gov). The data provided precise, functional evidence linking an SGCE mutation to altered neurotransmission, filling a gap between the genetic cause and the physiological effect. These findings were discussed by experts as confirmation that epsilon-sarcoglycan serves as a scaffolding or regulatory element at inhibitory synapses, supporting prior hypotheses (pmc.ncbi.nlm.nih.gov). In parallel, other studies of dystrophin and associated proteins at central synapses have reinforced the idea that the DGC proteins (including sarcoglycans) are crucial for proper synaptic architecture and plasticity (pmc.ncbi.nlm.nih.gov). Together, the research from 2022–2023 has shifted SGCE from being an “unknown function” gene to being recognized as a synaptic stability factor, especially in the context of inhibitory neural circuits.

• Non-Muscle Organ Expression (2025): Nicita et al. published a scoping review in 2025 (Biomolecules, July 2025) titled “Beyond Muscles: Sarcoglycan Expression in Non-Muscle Organs,” which summarizes a breadth of findings about sarcoglycans outside of skeletal muscle. This review highlights that epsilon-sarcoglycan (and other sarcoglycans) have widespread expression in various organs – including the brain, endocrine glands, adipose tissue, and even the oral mucosa (pmc.ncbi.nlm.nih.gov). It challenges the old assumption that sarcoglycans solely function in muscle, emphasizing instead their distinct regional and cell-type-specific roles across the body (pmc.ncbi.nlm.nih.gov). Specifically for the nervous system, the review notes a “widespread spot-like distribution” of sarcoglycan subunits in neurons and glial cells, implicating them in synaptic organization and neurotransmission (pmc.ncbi.nlm.nih.gov). The authors conclude that epsilon-sarcoglycan is crucial for synaptic function and that its dysfunction in vivo leads to imbalances in neurotransmission, particularly a deficit in GABAergic inhibitory signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They also discuss intriguing findings in non-neuronal tissues: for instance, in the retina (a part of the CNS), epsilon-sarcoglycan and other SGs are found at glial endfeet and support structural roles independent of dystrophin (pmc.ncbi.nlm.nih.gov). In the vasculature, enriched epsilon-sarcoglycan in larger blood vessels suggests a role in the molecular architecture of the blood-brain barrier or vascular mechanotransduction (pmc.ncbi.nlm.nih.gov). These insights from 2025 reflect an expert consensus that SGCE’s function extends well beyond what was initially recognized. The picture now is of epsilon-sarcoglycan as a versatile membrane scaffold that contributes to cellular integrity and signaling in many contexts – from stabilizing muscle fibers and maintaining synapses in the brain, to potentially supporting the structure of microvasculature and glandular cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

• Expert commentary and analysis: Leading scientists in the neurology and muscle biology fields have weighed in on SGCE. For example, in a 2016 commentary on myoclonus-dystonia, experts noted the curious fact that SGCE mutations cause no muscle pathology despite the protein being part of the muscle DGC (pmc.ncbi.nlm.nih.gov). This observation was discussed in terms of “tissue reserve” or redundancy – alpha-sarcoglycan in muscle can compensate for epsilon-sarcoglycan’s absence, whereas the brain has no equivalent backup (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The same commentary suggested that studying SGCE could bridge neurology and muscle biology, because it is one of the few molecules deeply involved in both muscle membrane mechanics and neural synaptic function. More recently, clinical geneticists have highlighted SGCE in the context of genetic counseling pearls. A 2023 case series by Surillo-Dahdah et al. (published in Cureus, Sept 2023) described SGCE mutation cases misdiagnosed as Tourette syndrome (pmc.ncbi.nlm.nih.gov). The authors stressed the importance of recognizing the inheritance pattern due to imprinting and testing for SGCE in abrupt-onset jerky movement disorders (pmc.ncbi.nlm.nih.gov). They also pointed out that many patients learn to self-medicate with alcohol (a GABA_A receptor modulator) which transiently relieves symptoms – an insight that retrospectively supports the notion that SGCE impacts GABAergic neurotransmission (since alcohol enhances GABA_A signaling) (www.ncbi.nlm.nih.gov). Such expert analyses reinforce that SGCE’s precise role is tied to inhibitory neurotransmission and provide real-world context on how understanding the gene’s function can lead to better diagnosis and patient guidance.

In summary, the latest research (2021–2024) has solidified SGCE’s identity as a gene encoding a multifunctional membrane protein. It is now appreciated not just as a structural component of muscle cell membranes, but as a crucial organizer of synaptic machinery in the brain, with broad expression in other organ systems. Authoritative reviews and studies up to 2024 highlight epsilon-sarcoglycan’s role in GABAergic synapse stability, its myriad isoforms and tissue-specific expression, and the pathophysiological mechanisms by which SGCE mutations lead to neurological disease (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). This growing body of work provides a much clearer framework for SGCE’s function, setting the stage for targeted therapeutic research and deeper exploration of how membrane complexes like the DGC contribute to both muscle integrity and neural circuit modulation.

Conclusion and Outlook

SGCE (epsilon-sarcoglycan) is a unique and essential gene that bridges muscle biology and neurobiology. The SGCE protein is a transmembrane glycoprotein embedded in the plasma membrane, where it forms part of the dystrophin-associated complex. Its primary function is structural: epsilon-sarcoglycan helps connect the internal cytoskeleton to the extracellular matrix, thereby stabilizing cell membranes in tissues that experience mechanical stress, such as muscle (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). At the same time, SGCE performs subtler roles in cell signaling domains – most prominently, it acts as a scaffolding protein in the brain, maintaining the architecture of inhibitory synapses and ensuring proper neurotransmitter receptor function (pmc.ncbi.nlm.nih.gov). The protein is predominantly localized to the cell surface (sarcolemma or neuronal membrane), where its large extracellular domain can interact with neighboring proteins and matrix components, and its small cytoplasmic tail may interface with cytosolic partners (www.dmd.nl) (pubmed.ncbi.nlm.nih.gov). SGCE’s importance in the central nervous system is underscored by the fact that its mutations cause myoclonus-dystonia, a movement disorder rooted in dysfunctional neural inhibition, without causing primary muscle disease (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This selective phenotype highlights how epsilon-sarcoglycan is indispensable for neuronal circuit stability, whereas muscle can compensate for its loss via other sarcoglycan isoforms.

From a biological process perspective, SGCE is involved in membrane organization, mechanoprotection, and synaptic transmission. It is a prime example of a structural protein that has downstream effects on signaling: by stabilizing receptors and ion channels at the membrane, epsilon-sarcoglycan influences pathways like GABAergic neurotransmission and possibly calcium homeostasis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Its role in the DGC also links it to pathways that govern cell survival under stress (since loss of DGC leads to muscle cell damage) and pathways that regulate neuronal excitability. The SGCE gene itself has intriguing regulatory features (notably maternally driven genomic imprinting), which add a genetic layer to its functional biology and must be considered in clinical contexts (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov).

Looking ahead, ongoing research is likely to further clarify epsilon-sarcoglycan’s molecular partners – identifying which proteins directly bind to its extracellular or cytosolic domains in the synapse or muscle membrane. Unanswered questions include how epsilon-sarcoglycan might participate in non-canonical complexes (e.g. the glial or vascular contexts where dystrophin is absent (pmc.ncbi.nlm.nih.gov)) and whether its absence triggers compensatory mechanisms in neurons. Better understanding of SGCE’s structure (for instance, through crystallography or cryo-EM of the sarcoglycan complex) could reveal how mutations disrupt its folding or interactions. From a medical standpoint, SGCE stands as a potential target for gene therapy or pharmacological upregulation. Because only the paternal allele is active, one therapeutic hypothesis is that drugs could “unsilence” the healthy maternal allele in carriers, restoring normal epsilon-sarcoglycan levels – an approach that has been pondered given the imprinting mechanism (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Additionally, since epsilon-sarcoglycan is not needed in skeletal muscle (due to redundancy), a therapy aimed at the brain would likely be well tolerated peripherally, simplifying safety considerations.

In conclusion, SGCE encodes a multifaceted protein that is a critical structural unit of membrane complexes in both muscle and neurons. Through its participation in the dystrophin glycoprotein complex, it confers mechanical stability to muscle cells, and through specialized isoforms in the brain, it maintains synaptic stability and inhibitory signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Epsilon-sarcoglycan exemplifies how a single gene can have broad, context-dependent roles – from muscle fiber integrity to fine-tuning neural communication. Ongoing research, especially recent studies in the 2020s, continue to refine our understanding of SGCE’s function, offering hope that this knowledge will translate into improved diagnostics and novel treatments for disorders like myoclonus-dystonia. The convergence of biochemical, genetic, and physiological evidence now provides a coherent narrative: SGCE is indispensable for the structural and functional integrity of certain cell membranes, and its loss leads to specific disease due to the breakdown of those membrane-associated processes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Future investigations will no doubt further elucidate the precise mechanisms by which epsilon-sarcoglycan supports cellular architecture and communication, solidifying its place as a key player in muscle and neuronal biology.

Citations

1. AnnotationURLCitation(end_index=601, start_index=422, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=The%20sarcoglycans%20are%20transmembrane%20proteins,reported%20in%20human%20cardiomyopathy%20patients')
2. AnnotationURLCitation(end_index=801, start_index=602, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=including%20dystroglycan%2C%20sarcoglycans%20and%20sarcospan,with%20sarcospan%2C%20strengthening%20the%20connection')
3. AnnotationURLCitation(end_index=1134, start_index=994, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=is%20maternally%20imprinted,contains%20three%20phosphorylation%20consensus%20sites')
4. AnnotationURLCitation(end_index=1295, start_index=1135, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20sarcoglycan%20complex%20was%20first,proteins%20with%20at%20least%20one')
5. AnnotationURLCitation(end_index=1658, start_index=1518, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=is%20maternally%20imprinted,contains%20three%20phosphorylation%20consensus%20sites')
6. AnnotationURLCitation(end_index=2124, start_index=1950, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=maternal%20imprinting%20and%2C%20therefore%2C%20based,derived%20SGCE%20alleles%20are%20expressed')
7. AnnotationURLCitation(end_index=2246, start_index=2125, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
8. AnnotationURLCitation(end_index=2548, start_index=2427, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
9. AnnotationURLCitation(end_index=2900, start_index=2758, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=are%20the%20most%20frequent%20genetic,specific%20isoforms%20and')
10. AnnotationURLCitation(end_index=3535, start_index=3356, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=The%20sarcoglycans%20are%20transmembrane%20proteins,reported%20in%20human%20cardiomyopathy%20patients')
11. AnnotationURLCitation(end_index=3709, start_index=3536, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
12. AnnotationURLCitation(end_index=4175, start_index=4004, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
13. AnnotationURLCitation(end_index=4349, start_index=4176, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
14. AnnotationURLCitation(end_index=4774, start_index=4575, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=including%20dystroglycan%2C%20sarcoglycans%20and%20sarcospan,with%20sarcospan%2C%20strengthening%20the%20connection')
15. AnnotationURLCitation(end_index=4948, start_index=4775, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
16. AnnotationURLCitation(end_index=5279, start_index=5119, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20sarcoglycan%20complex%20was%20first,proteins%20with%20at%20least%20one')
17. AnnotationURLCitation(end_index=5662, start_index=5506, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=multiple%20cell%20and%20tissue%20types,rather%20than%20in%20the%20muscle')
18. AnnotationURLCitation(end_index=5796, start_index=5663, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=suggesting%20that%20%CE%B5%20sarcoglycan%20can,97')
19. AnnotationURLCitation(end_index=6215, start_index=6076, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=replace%20%CE%B1%20,this%20syndrome%20is%20thought%20to')
20. AnnotationURLCitation(end_index=6378, start_index=6216, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=multiple%20cell%20and%20tissue%20types,of%20%CE%B1%20sarcoglycan%20null%20mice')
21. AnnotationURLCitation(end_index=6670, start_index=6561, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=%CE%B1,Sarcospan%20is%20a')
22. AnnotationURLCitation(end_index=7069, start_index=6898, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
23. AnnotationURLCitation(end_index=7243, start_index=7070, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
24. AnnotationURLCitation(end_index=7659, start_index=7492, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=match%20at%20L175%20between%20%CE%B1,and%20the%20sarcoglycans%20contain%20potential')
25. AnnotationURLCitation(end_index=8195, start_index=8056, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=In%20mammals%2C%20four%20types%20of,sarcoglycan%20%2889')
26. AnnotationURLCitation(end_index=8326, start_index=8196, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
27. AnnotationURLCitation(end_index=8565, start_index=8426, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=In%20mammals%2C%20four%20types%20of,sarcoglycan%20%2889')
28. AnnotationURLCitation(end_index=8968, start_index=8804, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=In%20mammals%2C%20four%20types%20of,are%20present%20with%20varying%20composition')
29. AnnotationURLCitation(end_index=9122, start_index=8969, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=The%20exact%20function%20of%20the,both%20muscle%20and%20nonmuscle%20tissues')
30. AnnotationURLCitation(end_index=9447, start_index=9326, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=On%20Northern%20blot%2C%20both%20Ettinger,13%20Straub%20et%20al')
31. AnnotationURLCitation(end_index=9598, start_index=9448, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=central%20nervous%20system%2C%20epsilon,at%20the%20cell%20surface%20and')
32. AnnotationURLCitation(end_index=9986, start_index=9793, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
33. AnnotationURLCitation(end_index=10117, start_index=9987, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
34. AnnotationURLCitation(end_index=10457, start_index=10318, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=replace%20%CE%B1%20,this%20syndrome%20is%20thought%20to')
35. AnnotationURLCitation(end_index=10624, start_index=10458, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=suggesting%20that%20%CE%B5%20sarcoglycan%20can,this%20syndrome%20is%20thought%20to')
36. AnnotationURLCitation(end_index=11058, start_index=10887, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
37. AnnotationURLCitation(end_index=11226, start_index=11059, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=match%20at%20L175%20between%20%CE%B1,and%20the%20sarcoglycans%20contain%20potential')
38. AnnotationURLCitation(end_index=11759, start_index=11600, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=dominant%20pattern%20with%20reduced%20penetrance,at%20the%20cell%20surface%20and')
39. AnnotationURLCitation(end_index=12099, start_index=11940, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=dominant%20pattern%20with%20reduced%20penetrance,at%20the%20cell%20surface%20and')
40. AnnotationURLCitation(end_index=12587, start_index=12463, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=To%20better%20understand%20the%20role,63')
41. AnnotationURLCitation(end_index=13030, start_index=12906, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=To%20better%20understand%20the%20role,63')
42. AnnotationURLCitation(end_index=13199, start_index=13031, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
43. AnnotationURLCitation(end_index=13523, start_index=13372, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Sgce%20is%20expressed%20primarily%20in,55%20Interestingly%2C%20only')
44. AnnotationURLCitation(end_index=14161, start_index=14012, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
45. AnnotationURLCitation(end_index=14577, start_index=14388, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=GABA_A%20receptors%2C%20particularly%20in%20hippocampal,dystonia%20%28MD%29%2C%20a%20movement%20disorder')
46. AnnotationURLCitation(end_index=14927, start_index=14747, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=GABA_A%20receptors%2C%20particularly%20in%20hippocampal,The%20evidence%20suggests%20that%20SGCE')
47. AnnotationURLCitation(end_index=15306, start_index=15157, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
48. AnnotationURLCitation(end_index=15699, start_index=15558, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=al.%20,deficit%20in%20GABAergic%20inhibitory%20signaling')
49. AnnotationURLCitation(end_index=16040, start_index=15891, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
50. AnnotationURLCitation(end_index=16445, start_index=16277, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
51. AnnotationURLCitation(end_index=16635, start_index=16446, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=GABA_A%20receptors%2C%20particularly%20in%20hippocampal,dystonia%20%28MD%29%2C%20a%20movement%20disorder')
52. AnnotationURLCitation(end_index=16964, start_index=16796, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
53. AnnotationURLCitation(end_index=17518, start_index=17332, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=and%20motor%20disturbances%20resembling%20myoclonus,deficit%20in%20GABAergic%20inhibitory%20signaling')
54. AnnotationURLCitation(end_index=17854, start_index=17696, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,together%2C%20these%20data%20may%20suggest')
55. AnnotationURLCitation(end_index=18145, start_index=18007, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,and%20LGMD%20type%202L')
56. AnnotationURLCitation(end_index=18581, start_index=18423, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,together%2C%20these%20data%20may%20suggest')
57. AnnotationURLCitation(end_index=19017, start_index=18866, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=The%20CNS,than%20participating%20directly%20in%20neurotransmission')
58. AnnotationURLCitation(end_index=19339, start_index=19207, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=Dp71,deficient%20conditions%20further%20implies')
59. AnnotationURLCitation(end_index=19722, start_index=19545, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=predominantly%20colocalize%20with%20M%C3%BCller%20glial,molecular%20partners%20yet%20to%20be')
60. AnnotationURLCitation(end_index=20077, start_index=19899, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=Adding%20further%20complexity%2C%20Boulay%20et,However%2C%20no%20cellular%20localization%20or')
61. AnnotationURLCitation(end_index=20452, start_index=20274, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=Adding%20further%20complexity%2C%20Boulay%20et,However%2C%20no%20cellular%20localization%20or')
62. AnnotationURLCitation(end_index=21057, start_index=20871, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=and%20motor%20disturbances%20resembling%20myoclonus,deficit%20in%20GABAergic%20inhibitory%20signaling')
63. AnnotationURLCitation(end_index=21224, start_index=21058, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=affects%20GABAergic%20synapses%20and%20contributes,synaptic%20scaffolding%20roles')
64. AnnotationURLCitation(end_index=21709, start_index=21569, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=is%20maternally%20imprinted,contains%20three%20phosphorylation%20consensus%20sites')
65. AnnotationURLCitation(end_index=22273, start_index=22114, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=dominant%20pattern%20with%20reduced%20penetrance,at%20the%20cell%20surface%20and')
66. AnnotationURLCitation(end_index=22398, start_index=22274, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=To%20better%20understand%20the%20role,63')
67. AnnotationURLCitation(end_index=22665, start_index=22544, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=On%20Northern%20blot%2C%20both%20Ettinger,13%20Straub%20et%20al')
68. AnnotationURLCitation(end_index=22825, start_index=22666, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=dominant%20pattern%20with%20reduced%20penetrance,at%20the%20cell%20surface%20and')
69. AnnotationURLCitation(end_index=23178, start_index=22989, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=GABA_A%20receptors%2C%20particularly%20in%20hippocampal,dystonia%20%28MD%29%2C%20a%20movement%20disorder')
70. AnnotationURLCitation(end_index=23719, start_index=23565, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=and%20transfected%20cells,Furthermore%2C%20torsinA%2C%20that%20is%20mutated')
71. AnnotationURLCitation(end_index=23957, start_index=23819, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=of%20wild,Furthermore%2C%20torsinA%2C%20that%20is%20mutated')
72. AnnotationURLCitation(end_index=24341, start_index=24232, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=%CE%B1,Sarcospan%20is%20a')
73. AnnotationURLCitation(end_index=24636, start_index=24527, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=%CE%B1,Sarcospan%20is%20a')
74. AnnotationURLCitation(end_index=25455, start_index=25334, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=On%20Northern%20blot%2C%20both%20Ettinger,13%20Straub%20et%20al')
75. AnnotationURLCitation(end_index=25830, start_index=25709, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=On%20Northern%20blot%2C%20both%20Ettinger,13%20Straub%20et%20al')
76. AnnotationURLCitation(end_index=26091, start_index=25932, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=dominant%20pattern%20with%20reduced%20penetrance,at%20the%20cell%20surface%20and')
77. AnnotationURLCitation(end_index=26464, start_index=26313, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Sgce%20is%20expressed%20primarily%20in,55%20Interestingly%2C%20only')
78. AnnotationURLCitation(end_index=26643, start_index=26465, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=Adding%20further%20complexity%2C%20Boulay%20et,However%2C%20no%20cellular%20localization%20or')
79. AnnotationURLCitation(end_index=27050, start_index=26886, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=In%20mammals%2C%20four%20types%20of,are%20present%20with%20varying%20composition')
80. AnnotationURLCitation(end_index=27283, start_index=27162, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=On%20Northern%20blot%2C%20both%20Ettinger,13%20Straub%20et%20al')
81. AnnotationURLCitation(end_index=27492, start_index=27376, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=antibody%2C%20Ettinger%20et%20al,expression%20due%20to%20a')
82. AnnotationURLCitation(end_index=27931, start_index=27773, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=in%20cardiac%20and%20skeletal%20muscle,both%20muscle%20and%20nonmuscle%20tissues')
83. AnnotationURLCitation(end_index=28053, start_index=27932, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=On%20Northern%20blot%2C%20both%20Ettinger,13%20Straub%20et%20al')
84. AnnotationURLCitation(end_index=28485, start_index=28292, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
85. AnnotationURLCitation(end_index=28616, start_index=28486, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
86. AnnotationURLCitation(end_index=29064, start_index=28893, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
87. AnnotationURLCitation(end_index=29606, start_index=29456, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=Dystrophy%20and%20referred%20to%20as,has%20important%20roles%20in%20both')
88. AnnotationURLCitation(end_index=30041, start_index=29842, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=including%20dystroglycan%2C%20sarcoglycans%20and%20sarcospan,with%20sarcospan%2C%20strengthening%20the%20connection')
89. AnnotationURLCitation(end_index=30215, start_index=30042, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
90. AnnotationURLCitation(end_index=30636, start_index=30465, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
91. AnnotationURLCitation(end_index=30805, start_index=30637, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=At%20the%20sarcolemma%2C%20the%20sarcoglycan,Mutations%20in%20the%20genes%20encoding')
92. AnnotationURLCitation(end_index=31619, start_index=31420, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=including%20dystroglycan%2C%20sarcoglycans%20and%20sarcospan,with%20sarcospan%2C%20strengthening%20the%20connection')
93. AnnotationURLCitation(end_index=31793, start_index=31620, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
94. AnnotationURLCitation(end_index=32763, start_index=32614, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
95. AnnotationURLCitation(end_index=33175, start_index=33000, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=inhibitory%20transmission.%20In%20%CE%B5,deficit%20in%20GABAergic%20inhibitory%20signaling')
96. AnnotationURLCitation(end_index=33896, start_index=33728, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
97. AnnotationURLCitation(end_index=34086, start_index=33897, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=GABA_A%20receptors%2C%20particularly%20in%20hippocampal,dystonia%20%28MD%29%2C%20a%20movement%20disorder')
98. AnnotationURLCitation(end_index=34575, start_index=34417, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,together%2C%20these%20data%20may%20suggest')
99. AnnotationURLCitation(end_index=34876, start_index=34738, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,and%20LGMD%20type%202L')
100. AnnotationURLCitation(end_index=35226, start_index=35088, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,and%20LGMD%20type%202L')
101. AnnotationURLCitation(end_index=35666, start_index=35517, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
102. AnnotationURLCitation(end_index=35835, start_index=35667, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
103. AnnotationURLCitation(end_index=36483, start_index=36353, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=Myoclonus,important%20role%20within%20the%20central')
104. AnnotationURLCitation(end_index=36614, start_index=36484, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
105. AnnotationURLCitation(end_index=36956, start_index=36826, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=Myoclonus,important%20role%20within%20the%20central')
106. AnnotationURLCitation(end_index=37538, start_index=37364, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=maternal%20imprinting%20and%2C%20therefore%2C%20based,derived%20SGCE%20alleles%20are%20expressed')
107. AnnotationURLCitation(end_index=37660, start_index=37539, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
108. AnnotationURLCitation(end_index=37916, start_index=37795, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
109. AnnotationURLCitation(end_index=38417, start_index=38224, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
110. AnnotationURLCitation(end_index=38609, start_index=38418, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=part%20of%20the%20dystrophin%E2%80%90associated%20protein,the%20molecular%20mechanisms%20underlying%20these')
111. AnnotationURLCitation(end_index=38979, start_index=38786, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
112. AnnotationURLCitation(end_index=39110, start_index=38980, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
113. AnnotationURLCitation(end_index=39749, start_index=39556, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
114. AnnotationURLCitation(end_index=40203, start_index=40054, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
115. AnnotationURLCitation(end_index=40379, start_index=40204, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=inhibitory%20transmission.%20In%20%CE%B5,deficit%20in%20GABAergic%20inhibitory%20signaling')
116. AnnotationURLCitation(end_index=41025, start_index=40871, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=and%20transfected%20cells,Furthermore%2C%20torsinA%2C%20that%20is%20mutated')
117. AnnotationURLCitation(end_index=41463, start_index=41325, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=of%20wild,Furthermore%2C%20torsinA%2C%20that%20is%20mutated')
118. AnnotationURLCitation(end_index=41901, start_index=41747, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=and%20transfected%20cells,Furthermore%2C%20torsinA%2C%20that%20is%20mutated')
119. AnnotationURLCitation(end_index=42768, start_index=42617, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=%2A%20Because%20about%205,individuals%20inherit%20the%20SGCE%20pathogenic')
120. AnnotationURLCitation(end_index=42890, start_index=42769, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
121. AnnotationURLCitation(end_index=43288, start_index=43167, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
122. AnnotationURLCitation(end_index=43822, start_index=43666, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=of%20either%20the%20effects%20of,an%20apparently%20negative%20family%20history')
123. AnnotationURLCitation(end_index=44676, start_index=44530, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=The%20gene%20produces%20a%20major,contains%20three%20phosphorylation%20consensus%20sites')
124. AnnotationURLCitation(end_index=45117, start_index=44961, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=multiple%20cell%20and%20tissue%20types,rather%20than%20in%20the%20muscle')
125. AnnotationURLCitation(end_index=45251, start_index=45118, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=suggesting%20that%20%CE%B5%20sarcoglycan%20can,97')
126. AnnotationURLCitation(end_index=46444, start_index=46302, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=are%20the%20most%20frequent%20genetic,specific%20isoforms%20and')
127. AnnotationURLCitation(end_index=46574, start_index=46445, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=nervous%20system,be%20strongly%20related%20to%20MD')
128. AnnotationURLCitation(end_index=46834, start_index=46692, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=are%20the%20most%20frequent%20genetic,specific%20isoforms%20and')
129. AnnotationURLCitation(end_index=47259, start_index=47130, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=nervous%20system,be%20strongly%20related%20to%20MD')
130. AnnotationURLCitation(end_index=48071, start_index=47922, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
131. AnnotationURLCitation(end_index=48558, start_index=48417, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=al.%20,deficit%20in%20GABAergic%20inhibitory%20signaling')
132. AnnotationURLCitation(end_index=49091, start_index=48920, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=associated%20with%20SGCE%20%28%CE%B5,deficit%20in%20GABAergic%20inhibitory%20signaling')
133. AnnotationURLCitation(end_index=49482, start_index=49314, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
134. AnnotationURLCitation(end_index=50347, start_index=50172, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=This%20scoping%20review%20explores%20the,cells%2C%20implicating%20their%20involvement%20in')
135. AnnotationURLCitation(end_index=50695, start_index=50520, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=This%20scoping%20review%20explores%20the,cells%2C%20implicating%20their%20involvement%20in')
136. AnnotationURLCitation(end_index=51073, start_index=50911, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=highlights%20the%20widespread%20presence%20of,At%20the%20same%20time%2C%20the')
137. AnnotationURLCitation(end_index=51463, start_index=51292, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=associated%20with%20SGCE%20%28%CE%B5,deficit%20in%20GABAergic%20inhibitory%20signaling')
138. AnnotationURLCitation(end_index=51650, start_index=51464, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=and%20motor%20disturbances%20resembling%20myoclonus,deficit%20in%20GABAergic%20inhibitory%20signaling')
139. AnnotationURLCitation(end_index=52031, start_index=51880, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=The%20CNS,than%20participating%20directly%20in%20neurotransmission')
140. AnnotationURLCitation(end_index=52393, start_index=52215, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=Adding%20further%20complexity%2C%20Boulay%20et,However%2C%20no%20cellular%20localization%20or')
141. AnnotationURLCitation(end_index=52991, start_index=52825, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=affects%20GABAergic%20synapses%20and%20contributes,synaptic%20scaffolding%20roles')
142. AnnotationURLCitation(end_index=53150, start_index=52992, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=assumption%20that%20their%20function%20is,At%20the%20same%20time%2C%20the')
143. AnnotationURLCitation(end_index=53658, start_index=53465, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
144. AnnotationURLCitation(end_index=54054, start_index=53861, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
145. AnnotationURLCitation(end_index=54185, start_index=54055, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
146. AnnotationURLCitation(end_index=54779, start_index=54654, title='Two-Generation Epsilon-Sarcoglycan Gene (SGCE) Mutation-Associated Myoclonus-Dystonia (DYT-SGCE) Misdiagnosed as Tourette’s Syndrome: A Case Series - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10576872/#:~:text=Myoclonus,Muacevic%2C%20John%20R%20Adler')
147. AnnotationURLCitation(end_index=55065, start_index=54940, title='Two-Generation Epsilon-Sarcoglycan Gene (SGCE) Mutation-Associated Myoclonus-Dystonia (DYT-SGCE) Misdiagnosed as Tourette’s Syndrome: A Case Series - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10576872/#:~:text=Myoclonus,Muacevic%2C%20John%20R%20Adler')
148. AnnotationURLCitation(end_index=55508, start_index=55352, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=of%20either%20the%20effects%20of,an%20apparently%20negative%20family%20history')
149. AnnotationURLCitation(end_index=56470, start_index=56321, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
150. AnnotationURLCitation(end_index=56613, start_index=56471, title='ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33886091/#:~:text=are%20the%20most%20frequent%20genetic,specific%20isoforms%20and')
151. AnnotationURLCitation(end_index=57562, start_index=57391, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
152. AnnotationURLCitation(end_index=57736, start_index=57563, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=protein%20and%20a%20receptor%20for,with%20sarcospan%2C%20strengthening%20the%20connection')
153. AnnotationURLCitation(end_index=58141, start_index=57992, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SGs%2C%20particularly%20%CE%B5,its%20dysfunction%20in%20MD%20may')
154. AnnotationURLCitation(end_index=58549, start_index=58409, title='epsilon-Sarcoglycan', type='url_citation', url='https://www.dmd.nl/sgce_home.html#:~:text=is%20maternally%20imprinted,contains%20three%20phosphorylation%20consensus%20sites')
155. AnnotationURLCitation(end_index=58709, start_index=58550, title='SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/17200151/#:~:text=dominant%20pattern%20with%20reduced%20penetrance,at%20the%20cell%20surface%20and')
156. AnnotationURLCitation(end_index=59130, start_index=58937, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=Myoclonus%E2%80%90dystonia%20is%20a%20neurogenic%20movement,the%20molecular%20mechanisms%20underlying%20these')
157. AnnotationURLCitation(end_index=59261, start_index=59131, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=Nonmuscle%20forms%20of%20the%20sarcoglycan,167')
158. AnnotationURLCitation(end_index=60028, start_index=59842, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=and%20motor%20disturbances%20resembling%20myoclonus,deficit%20in%20GABAergic%20inhibitory%20signaling')
159. AnnotationURLCitation(end_index=60167, start_index=60029, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=DGC%20has%20a%20critical%20role,and%20LGMD%20type%202L')
160. AnnotationURLCitation(end_index=60738, start_index=60564, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=maternal%20imprinting%20and%2C%20therefore%2C%20based,derived%20SGCE%20alleles%20are%20expressed')
161. AnnotationURLCitation(end_index=60860, start_index=60739, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
162. AnnotationURLCitation(end_index=61378, start_index=61252, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=Dp71,molecular%20partners%20yet%20to%20be')
163. AnnotationURLCitation(end_index=62177, start_index=62003, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=maternal%20imprinting%20and%2C%20therefore%2C%20based,derived%20SGCE%20alleles%20are%20expressed')
164. AnnotationURLCitation(end_index=62299, start_index=62178, title='SGCE Myoclonus-Dystonia - GeneReviews® - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK1414/#:~:text=,often%20the%20offspring%20is%20symptomatic')
165. AnnotationURLCitation(end_index=63048, start_index=62877, title='The Dystrophin Complex: structure, function and implications for therapy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4767260/#:~:text=The%20dystrophin%20complex%20stabilizes%20the,plasma%20membrane%20and%20myofiber%20loss')
166. AnnotationURLCitation(end_index=63235, start_index=63049, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=and%20motor%20disturbances%20resembling%20myoclonus,deficit%20in%20GABAergic%20inhibitory%20signaling')
167. AnnotationURLCitation(end_index=64115, start_index=63947, title='Myoclonus dystonia and muscular dystrophy: ɛ‐sarcoglycan is part of the dystrophin‐associated protein complex in brain - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5129563/#:~:text=From%20a%20clinical%20perspective%2C%20our,dystrophies%2C%20and%20other%20forms%20of')
168. AnnotationURLCitation(end_index=64302, start_index=64116, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=and%20motor%20disturbances%20resembling%20myoclonus,deficit%20in%20GABAergic%20inhibitory%20signaling')